Metcash Limited (OTCMKTS:MHTLY) Given Consensus Rating of “Hold” by Analysts

Share on StockTwits

Metcash Limited (OTCMKTS:MHTLY) has been given a consensus recommendation of “Hold” by the six analysts that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation.

MHTLY has been the topic of several research reports. Citigroup raised shares of Metcash from a “sell” rating to a “neutral” rating in a research note on Monday, November 25th. UBS Group downgraded shares of Metcash from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th.

Shares of OTCMKTS:MHTLY traded down $1.02 during midday trading on Monday, hitting $11.67. The company’s stock had a trading volume of 200 shares, compared to its average volume of 367. The business’s 50 day simple moving average is $12.07 and its 200 day simple moving average is $11.85. Metcash has a 12-month low of $10.00 and a 12-month high of $12.69.

Metcash Company Profile

Metcash Limited operates as a wholesale distribution and marketing company in Australia and New Zealand. It operates through Food, Liquor, and Hardware segments. The Food segment distributes a range of products and services to independent supermarket and convenience retail outlets. The Liquor segment engages in the distribution of liquor products to independent retail outlets and hotels.

See Also: Profit margin is different from the revenue

Analyst Recommendations for Metcash (OTCMKTS:MHTLY)

Receive News & Ratings for Metcash Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metcash and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

QuickLogic  Downgraded by Zacks Investment Research to Sell
QuickLogic Downgraded by Zacks Investment Research to Sell
Regeneron Pharmaceuticals  Upgraded to “Buy” by BidaskClub
Regeneron Pharmaceuticals Upgraded to “Buy” by BidaskClub
Proofpoint  Raised to “Buy” at BidaskClub
Proofpoint Raised to “Buy” at BidaskClub
Omeros  Upgraded at BidaskClub
Omeros Upgraded at BidaskClub
360 Finance  Rating Increased to Buy at ValuEngine
360 Finance Rating Increased to Buy at ValuEngine
Kiniksa Pharmaceuticals  Downgraded by Zacks Investment Research to “Sell”
Kiniksa Pharmaceuticals Downgraded by Zacks Investment Research to “Sell”


 
© 2006-2020 Zolmax.